RxDoctor Payments Data

Jennifer Richardson, MD

Rheumatology · Columbus, OHNPI 1275511057

Payments from drug & device makers

$2,373in general payments, 2019–2025

Across 107 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$785
  • Novartis$374
  • Amgen$340
  • GSK$214
  • Pfizer$181
  • Johnson & Johnson$150
  • plus $329 from 9 others

What the payments were for

  • Food & beverage$2,373100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie43$785
Novartis13$374
Amgen(2 entities)15$340
GSK12$214
Pfizer10$181
Johnson & Johnson1$150
UCB, Inc.4$146
Genentech USA, Inc.2$38
Aurinia Pharma U.S., Inc.1$25
AstraZeneca1$23
Organon1$23
Lilly USA, LLC1$22
Biocon Biologics Inc1$21
Ferring Pharmaceuticals Inc.1$17
Mallinckrodt Enterprises LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,373 in reported general payments places this provider in the 55th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,213,121
Medicare patients
421
Services billed
63,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib93$585,915
Humira(Cf) PenAdalimumab57$578,834
Enbrel SureclickEtanercept33$288,227
Cosentyx Sensoready (2 Pens)Secukinumab12$134,356
Xeljanz XrTofacitinib Citrate17$95,215
SimponiGolimumab13$75,786
OtezlaApremilast11$53,001
Leflunomide216$17,961
Hydroxychloroquine Sulfate308$17,915
MethotrexateMethotrexate Sodium371$13,027
Celecoxib91$5,348
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen120$3,497
Lidocaine18$2,315
Azathioprine53$2,282
Cevimeline Hcl22$2,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$785$585,91593 claims
Johnson & JohnsonSimponi$150$75,78613 claims
AmgenOtezla$340$53,00111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →